AbbVie reports positive long-term results for atogepant in migraine prevention
AbbVie Inc. (NYSE: ABBV) has announced encouraging findings from an interim analysis of a 156-week extension study, assessing the long-term safety and effectiveness of atogepant, an oral medication designed for migraine prevention. Conducted over three years, this Phase 3, open-label study involves participants with chronic or episodic migraine. According to the data, atogepant continues to […]